Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 4.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,582,874 shares of the company's stock after selling 166,612 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 2.49% of Denali Therapeutics worth $73,019,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Rhumbline Advisers grew its position in Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after acquiring an additional 885 shares during the last quarter. Sterling Capital Management LLC raised its holdings in shares of Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Denali Therapeutics by 0.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company's stock worth $4,250,000 after acquiring an additional 1,702 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its stake in Denali Therapeutics by 32.2% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the period. 92.92% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DNLI. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target for the company. Cantor Fitzgerald upgraded shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. B. Riley restated a "buy" rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. HC Wainwright cut their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Bank of America cut their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $33.71.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock traded down $0.50 on Friday, hitting $13.04. 246,835 shares of the company traded hands, compared to its average volume of 1,108,846. The business has a 50-day simple moving average of $13.86 and a 200 day simple moving average of $18.71. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The stock has a market capitalization of $1.89 billion, a P/E ratio of -4.77 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the prior year, the firm posted ($0.68) earnings per share. Research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.